SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs quarterly results drew attention after traders highlighted a sizable earnings and revenue beat, though the share reaction was muted and volatile. The debate centers on whether strong growth can outweigh heavy spending, valuation concerns and a looming share unlock.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly results beat earnings expectations, but weaker forward guidanceparticularly the Q4 outlookprompted a sharp post-report selloff. Traders are split between viewing the drop as justified by slowing growth and buying it as an overreaction to an otherwise solid quarter.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A sharp rebound has focused attention on the approaching 80-event trigger for SELLASs Phase 3 REGAL trial and its eventual final analysis, with traders also pointing to SLS009 updates as potential catalysts. Buyout and data-leak theories are circulating, but no deal or new trial result is confirmed; some traders view the move as a speculative rebound without company news.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgicals Q3 results beat expectations, but shares sold off, prompting traders to call it a sell the news reaction. Bulls see the drop as an overreaction to strong results, while skeptics point to weaker reported earnings after a one-time litigation charge and elevated expenses.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

The FAAs certification of Boeings 737 MAX 10 is the main catalyst, clearing a long-standing regulatory hurdle for a model tied to a sizable share of the 737 backlog. Traders are frustrated that the approval has not lifted the stock, arguing it may be priced in and that production, deliveries, and cash generation remain the bigger tests.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

Uniteds quarterly results narrowly missed expectations as sharply higher fuel costs pressured profitability despite revenue growth, while upbeat forward revenue guidance and resilient travel demand offered a counterpoint. Traders are divided between concern that fuel will keep squeezing margins and optimism that demand and pricing can offset the costs.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea shares are selling off after reports that it plans to list fintech arm Monee and launch an AI cloud business, despite some traders viewing the moves as potential growth opportunities. The community is divided over whether the plans could unlock value or create uncertainty and spending concerns, while many point to the stocks sharp technical breakdown.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE fell despite beating quarterly expectations and raising its outlook, with traders focused on rising costs, weaker cash conversion, and an insurance loss rather than strong orders and demand. The reaction sparked frustration over repeated selloffs after earnings, while some traders viewed the decline as a buying opportunity.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IRENs sharp selloff and underperformance versus other AI data-center peers are fueling debate amid concerns about neocloud funding, AI infrastructure returns and potential sector consolidation. Traders are split over whether the decline reflects business, dilution and execution risks or an oversold move; bulls cite co-CEO Daniel Roberts comments that data-center assets carry no debt and customer prepayments help fund GPU costs, while skeptics remain unconvinced.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs rise is being attributed mainly to strength across biotech, with traders also citing Silence Therapeutics acquisition as a signal of broader pharma interest in siRNA. The community is divided on whether the move reflects sector momentum or company-specific buying; speculation about a data leak remains unconfirmed.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SRPTs move is being linked to strength across biotech and a read-through from the Silence Therapeutics acquisition, which traders say highlights large-pharma interest in siRNA therapies. Others view the rise as a sector-driven move rather than a Sarepta-specific catalyst, while upcoming DM1 and FSHD data remain a focus.

The move appears tied largely to broader biotech strength, with traders noting gains in XBI and peers such as Moderna and Novavax. Some also pointed to the Silence Therapeutics acquisition as support for siRNA valuations, but no SRPT-specific catalyst was confirmed.

Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new preclinical data at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) demonstrating that SRP-1003, the company's investigational small interfering RNA...

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (KSF), announces that KSF has commenced an investigation into Sarepta Therapeutics, Inc. (NasdaqGS: SRPT) (Sarepta or the Company). Sarepta is a biopharmaceutical company focused on...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Sept. 30, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sareptas 2024 Employment Commencement Incentive Plan, as a...

Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new data at the 31st Annual Congress of the World Muscle Society (WMS) that provide evidence of clinically meaningful functional benefit of ELEVIDYS (delandistrogene moxeparvovec...

Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data from its portfolio of treatments for Duchenne muscular dystrophy at the 31st Annual Congress of the World Muscle Society (WMS), taking place Sept. 29 - Oct. 3, in Hiroshima...

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data at the 27th Annual Neuromuscular Study Group (NMSG) Scientific Meeting, taking place Sept. 25-27, 2026, in San Antonio, Texas. Sarepta will present seven posters at NMSG...

NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week — DYN, SRPT Slip In Sympathy

Equity

The company said on Tuesday that its experimental drug del-desiran failed in a late-stage trial. 

A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower

Sarepta Therapeutics shares react to Novartis Phase 3 trial results in DM1 while Sarepta progresses its SRP-1003 RNA therapy clinical trials.read more...

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 academic year. Of the academic scholarships, 20 will be awarded to individuals living with Duchenne...

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT PR...

Bullish Sentiment

<ul class="summary-bullets"><li>The Phase 3 HARBOR study compared the experimental drug with a dummy treatment in people with DM1, a progressive illness that stiffens and weakens muscles and has no approved medicine.</li><li>Patients did not open a clenched hand faster in a statistically meaningful way on the trial’s main measure.</li><li>The disappointment follows Friday’s failure of pelacarsen, Novartis’s late-stage heart drug licensed from Ionis Pharmaceuticals.</li></ul>Novartis shares (NVS) sold off hard on Tuesday after the company said a late-stage study of del-desiran in myotonic dystrophy type 1 failed its primary test, marking its second failed trial in a week.&nbsp;&nbsp;The stock closed down 14%, clocking its worst day in over 20 years.&nbsp;<h2 class="st-heading-2">Hand-Stiffness Test Falls Short</h2>The Phase 3 HARBOR study compared the experimental drug with a dummy treatment in people with DM1, a progressive illness that stiffens and weakens muscles and has no approved medicine. Patients did not open a clenched hand faster in a statistically meaningful way on the trial’s main measure. Novartis said the drug showed signs of activity on secondary measures and that safety was in line with earlier studies. The company is reviewing the full data and will talk with regulators about next steps.“Developing therapies for a complex disease like DM1 remains challenging, and setbacks are part of scientific progress,” said Shreeram Aradhye, Novartis’s president of development and chief medical officer.&nbsp;Del-desiran came into the company through its $12 billion purchase of Avidity Biosciences. Novartis said work continues on two other drugs from that deal and that its longer-term sales growth outlook is unchanged.&nbsp;<h2 class="st-heading-2">A Second Miss In One Week</h2>The disappointment follows Friday’s failure of pelacarsen, Novartis’s late-stage heart drug licensed from Ionis Pharmaceuticals. That study lowered the targeted blood fat but did not cut the risk of heart attacks, strokes and related events.&nbsp;“These are not the results we hoped for,” Aradhye said on Friday.&nbsp;<h2 class="st-heading-2">Other Stocks Slide; Analysts Split On Fallout</h2>Companies working on related muscle diseases moved with Novartis. Shares of Dyne Therapeutics (DYN), which is developing zbasivarsen for DM1, fell 16%. Sarepta Therapeutics (SRPT) was down 7%.Jefferies said the HARBOR miss “may negatively impact the space,” but argued Dyne’s zbasivarsen could still work and “even generate superior data.” The firm called Dyne the “frontrunner” in DM1 after Novartis’s failure and kept a Buy rating and $50 target.&nbsp;Stifel said many investors had treated HARBOR as likely to succeed and that Dyne will stay under pressure. The bear case, it said, is that the drugs look similar and Dyne’s pivotal study is smaller. Stifel still likes Dyne’s scientific case, would buy the selloff, and rates the stock Buy with a $37 target.&nbsp;H.C. Wainwright kept a Sell rating and $5 target on Sarepta. It said the miss is “particularly relevant” as support for Sarepta’s marketed Duchenne story has faded, and it raises the bar for Sarepta’s SRP-1003 being developed to treat DM1.&nbsp;<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around NVS stock remained ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.&nbsp;A few Stocktwits users opined that Novartis should strengthen its pipeline with other buyouts.&nbsp;<stembedurl>https://stocktwits.com/CityLife511/message/663805749</stembedurl><stembedurl>https://stocktwits.com/HalfTrader/message/663812506</stembedurl>Another user called Tuesday's selloff a good opportunity and expressed hopes for a recovery.<stembedurl>https://stocktwits.com/SenefAS/message/663779750</stembedurl><a href="https://stocktwits.com/symbol/NVS">NVS stock</a> is trading flat year-to-date.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nflx-is-opening-up-box-office-numbers-for-six-upcoming-films-says-report-is-netflix-rethinking-its-movie-theater-strategy/cZtE4kpRJyR">NFLX Is Opening Up Box Office Numbers For Six Upcoming Films, Says Report — Is Netflix Rethinking Its Movie-Theater Strategy?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

The company said on Tuesday that its experimental drug del-desiran failed in a late-stage trial.

Dyne Therapeutics Inc

Novartis AG

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

Investors are closely watching upcoming clinical readouts for the DM1 and FSHD programs following encouraging validation from sector peers.

Traders are monitoring heavy short interest and significant closing volume for potential breakout moves toward higher price targets.

The stock is showing signs of building strength after establishing higher lows and reclaiming key technical levels like the 50-day moving average.

Current Price	$19.17
Prev Close	$17.73
Open	$17.74
Dividend Yield	0.00%
50-Day Moving Average	$19.20
Beta	1.30
Avg. Volume	2.94M
PE Ratio	-6.12

52-Week High	$24.68
52-Week Low	$14.68
Market Capitalization	$1.87B
EPS (Annual)	-$7.13
Price to Book	1.23
Revenue Per Employee	$2.63M

Feed

News

Sentiment

Earnings

Fundamentals

Info

SRPT Fundamentals